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Hybrid Thoracoscopic
and Transvenous Catheter
Ablation of Atrial Fibrillation
Is This the Answer
We Are Searching For?*
Hugh Calkins, MD
Baltimore, Maryland
During the past decade, catheter ablation of atrial fibrilla-
tion (AF) has emerged as an important treatment option for
patients with symptomatic AF refractory to 1 or more
antiarrhythmic agents. Electrical isolation of the pulmonary
vein musculature (PVI) has been identified as the primary
end point for both catheter-based and surgical AF ablation
procedures (1). Despite the widespread adoption of catheter
ablation for treatment of patients with AF, the long-term
efficacy of the procedure needs to improve, especially for
patients with persistent and long-standing persistent AF.
See page 54
In this issue of the Journal, Pison et al. (2) report the
results of an ambitious prospective single-center study of 26
consecutive patients who underwent a hybrid thoracoscopic
surgical and transvenous catheter ablation procedure over a
21-month period. These patients were followed closely for a
mean of 470  154 days with serial 7-day Holter monitor-
ing. Ablation success was defined in accordance with the
Heart Rhythm Society, European Heart Rhythm Associa-
tion, and European Cardiac Arrhythmia Society consensus
document as freedom from AF, atrial flutter, or atrial
tachycardia lasting 30 seconds or longer after a 3-month
blanking period. Fifteen patients had paroxysmal AF, 10
persistent AF, and 1 long-standing persistent AF. One or
more catheter ablation procedures had previously failed in
10 patients. The ablation strategy involved a combined
minimally invasive, off-pump thoracoscopic surgical ap-
proach using the Atricure bipolar radiofrequency clamp
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The use of endocardial catheter ablation allowed the
completion of lesion sets that could not be completed
surgically, especially the mitral isthmus line and the cavo-
tricuspid isthmus ablation line. Endocardial ablation,
guided by epicardial mapping rather than a 3-dimensional
mapping system, was also used to fill gaps in the surgically
applied lesions. The precise lesion set in a given patient was
tailored on the basis of concomitant disease (patients with
chronic obstructive pulmonary disease had the left pulmo-
nary veins isolated with a cryoballoon, PVI in 26, posterior
box in 22, bicaval line in 9, mitral isthmus in 3, and CTI in
3). The mean procedure time was 280  84 min, with a
range of 195 to 505 min. Follow-up visits, which included
7-day Holter monitoring, were set up at 3, 6, 9, 12, and 18
months after ablation. All procedures were performed at a
single center by the same cardiac surgeon and electrophysi-
ologist. The single procedure success rate was 83%. With
the inclusion of repeat endocardial ablation procedures
performed in 2 patients, the success rate increased to 92%.
The only complication that occurred was a pleural effusion
requiring drainage in 1 patient. The investigators conclude
that a combined transvenous endocardial and thoracoscopic
epicardial ablation procedure for paroxysmal and recent
persistent AF has a single-procedure success rate of 83% at
1 year and that recurrent arrhythmias can be addressed with
catheter ablation or antiarrhythmic drug therapy.
This landmark study is a welcome addition to the
published research on catheter and surgical AF ablation. I
commend Pison et al. (2) for their enormous efforts to
complete this novel clinical trial.
Despite the small number of patients, the duration,
intensity of monitoring, and completeness of follow-up are
to be commended. The remarkably low complication rate
speaks to the expertise of the operators and center and is also
to be congratulated. In writing this editorial, I am charged
with helping interpret the results of this study in the context
of both my own experience with catheter ablation as well as
the considerable body of previously published research on
catheter and surgical AF ablation. I would like to offer 2
thoughts for readers’ consideration.
It must be recognized and appreciated that this is the first
publication to report the outcomes of a “hybrid” thoraco-
scopic surgical and transvenous catheter ablation procedure
for AF. As outlined in the report, there exists a clear
rationale for this approach, as some ablation lesions that are
incorporated into the well-established Cox maze lesion
cannot be accomplished using a minimally invasive, off-
pump surgical approach. And other lesions that are part of
this ablation strategy may be more successfully applied using
currently available surgical ablation tools (i.e., PVI, where
the rate of permanent long-term PVI with catheter ablation
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high single-procedure efficacy of this approach. However,
the enthusiasm for this “hybrid” ablation strategy must be
tempered by some important limitations that must be
recognized with both the ablation strategy and the design of
this study. It is unfortunate that the investigators did not
choose to take on a series of patients with long-standing
persistent AF, especially a series of patients with long-
standing AF of many years’ duration and dilated left atria,
for it is in this subset of patients that the results of catheter
ablation have been most disappointing. Hopefully, the
investigators are carrying out this trial at the present time.
Another limitation of the “hybrid” ablation strategy is that
it is a logistical nightmare. Not only are experts in both
catheter ablation and surgical ablation required, but they
must both be available in the same hospital, on the same
day, at the same time, and for as long as 8 h (the longest
procedure in this report required 505 min). This may
explain why it required 21 months to perform the 26
procedures in this trial. It is my impression that it is
extremely rare to have tremendous expertise with catheter
ablation and surgical AF ablation at the same institution.
Most centers are expert at one or the other. Further studies
need to examine the feasibility of a staged hybrid approach,
in which the surgical ablation is performed on a separate day
from the catheter ablation part of the study. Once a staged
strategy is considered, one wonders if it would be preferable
to perform the surgical ablation with PVI first and perform
the catheter ablation part of the procedure only if AF recurs
after the initial surgical procedure. I suspect that for some
patients, all that is needed is PVI.
The remarkably high ablation success rate reported in this
trial is truly remarkable. This important result has implica-
tions for the entire field of AF ablation, because it is further
evidence that AF ablation procedures that are based on the
cornerstone of PVI are effective, especially for treatment of
patients with paroxysmal and early persistent AF. And
when performed by highly experienced operators at experi-
enced centers, these procedures can be performed safely.
What remains less clear is the important issue of which
lesions or lesion sets are needed and what is the best end
point for the procedure. This study does little to provide
new knowledge that can be applied to this important
question. This statement reflects the fact that most patients
in this series had paroxysmal AF, and only 1 patient had
long-standing persistent AF. Furthermore, ablation lesionswith the exception of PVI were “tailored” on the basis of
inducibility, concomitant patient diseases, AF type, and
operator preference. The resultant “special sauce” applied to
each patient may not be replicable by other centers and
operators. As noted previously and shown on a patient-by-
patient basis in Table 1 of the report (2), the only standard
lesion applied to all patients was PVI. Despite the theoret-
ical benefit of a hybrid approach to accomplish a complete
mitral line and cavotricuspid line, these lesions were each
created in only 3 of the 26 patients.
At the end of the day, is hybrid thoracoscopic and
transvenous catheter ablation of AF the answer we are
searching for? In my opinion, the answer is “not yet,” and
certainly not on the basis of the very limited worldwide
experience with this approach. It is clear that more research
is needed. In particular, I would like to see the results of a
much larger, multicenter trial of “hybrid AF ablation” that
targets a population of patients with long-standing persis-
tent AF and dilated left atria. Those involved in this field
are grateful to Pison et al. (2) for bringing forth the concept
of “hybrid AF ablation.”
Reprint requests and correspondence: Dr. Hugh Calkins, Johns
Hopkins Hospital, 530 Carnegie, 600 North Wolfe Street, Balti-
more, Maryland 21287-6568. E-mail: hcalkins@jhmi.edu.
REFERENCES
1. Calkins H, Kuck KH, Cappato R, et al. 2012 HRS/EHRA/ECAS
expert consensus statement on catheter and surgical ablation of atrial
fibrillation: recommendations for patient selection, procedural tech-
niques, patient management and follow-up, definitions, endpoints, and
research trial design: a report of the Heart Rhythm Society (HRS) Task
Force on Catheter and Surgical Ablation of Atrial Fibrillation. Devel-
oped in partnership with the European Heart Rhythm Association
(EHRA), a registered branch of the European Society of Cardiology
(ESC) and the European Cardiac Arrhythmia Society (ECAS); and in
collaboration with the American College of Cardiology (ACC), Amer-
ican Heart Association (AHA), the Asia Pacific Heart Rhythm Society
(APHRS), and the Society of Thoracic Surgeons (STS). Endorsed by
the governing bodies of the American College of Cardiology
Foundation, the American Heart Association, the European Cardiac
Arrhythmia Society, the European Heart Rhythm Association, the
Society of Thoracic Surgeons, the Asia Pacific Heart Rhythm Society,
and the Heart Rhythm Society. Heart Rhythm 2012;9:632–96.
2. Pison L, La Meir M, van Opstal J, Blaauw Y, Maessen J, Crijns HJ.
Hybrid thoracoscopic surgical and transvenous catheter ablation of atrial
fibrillation. J Am Coll Cardiol 2012;60:54–61.
Key Words: ablation y arrhythmia y atrial fibrillation y catheter
ablation of atrial fibrillation y surgical atrial fibrillation ablation y
thoracoscopic atrial fibrillation ablation.
